Lecanemab for treatment of individuals with early Alzheimer’s Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes

Authors

Amanda Goodwin (ORCID: https://orcid.org/0000-0002-1488-6549)
Michio Kanekiyo
Mark Hodgkinson
Shobha Dhadda (ORCID: https://orcid.org/0000-0002-7290-7168)
Sarah J. Trafford
Christopher Kipps (ORCID: https://orcid.org/0000-0002-5205-9712)
Steven J. Hersch (ORCID: https://orcid.org/0000-0001-6186-0133)
María Martín (ORCID: https://orcid.org/0000-0001-5757-5938)
Richard W. Perry
Marco Bozzali
Giancarlo Logroscino
Lynn Kramer
Michael Irizarry

Institutions

Université Fédérale de Toulouse Midi-Pyrénées (FR)
Heidelberg University (DE)
University Hospital Heidelberg (DE)
University Hospital Southampton NHS Foundation Trust (GB)
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
Central Institute of Mental Health (DE)
Eisai (United Kingdom) (GB)
Eisai (United States) (US)
Imperial College London (GB)
University of Bari Aldo Moro (IT)

Publication Details

Journal: The Journal of Prevention of Alzheimer s Disease
Published: 2026-02-13
DOI: https://doi.org/10.1016/j.tjpad.2026.100507
Primary Topic: Alzheimer's disease research and treatments
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Lecanemab for treatment of individuals with early Alzheimer’s Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes

Amanda Goodwin, Michio Kanekiyo, Mark Hodgkinson, Shobha Dhadda et al.

Feb 13, 2026

The Journal of Prevention of Alzheimer s Disease

Alzheimer's disease research and treatments

article

Lecanemab for treatment of individuals with early Alzheimer’s Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes

Amanda Goodwin, Michio Kanekiyo, Mark Hodgkinson, Shobha Dhadda, Sarah J. Trafford, Christopher Kipps, Steven J. Hersch, María Martín, Richard W. Perry, Marco Bozzali, Giancarlo Logroscino, Lynn Kramer, Michael Irizarry

February 13, 2026article en

Abstract

No abstract available for this paper.

The Journal of Prevention of Alzheimer s DiseaseVol. 13(4)

Université Fédérale de Toulouse Midi-Pyrénées (FR), Heidelberg University (DE), University Hospital Heidelberg (DE), University Hospital Southampton NHS Foundation Trust (GB), Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT), Central Institute of Mental Health (DE), Eisai (United Kingdom) (GB), Eisai (United States) (US), Imperial College London (GB), University of Bari Aldo Moro (IT)

Good health and well-being

Openalex Percentile: Top 55%

Alzheimer's disease research and treatments

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Lecanemab for treatment of individuals with early Alzheimer’s Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes — Amanda Goodwin, Michio Kanekiyo, et al. · The Journal of Prevention of Alzheimer s Disease (2026) | TGRS Research Map | TGRS